First Real-World Study Supports Sotatercept for PAH
A real-world study has shown that sotatercept is safe and effective for patients with pulmonary arterial hypertension (PAH). Conducted by Mayo Clinic researchers, the study involved 91 patients and reported significant improvements in exercise capacity and biomarkers. The findings were presented at the American Thoracic Society conference, highlighting the drug's potential in clinical practice.
- ▪The study assessed the safety and effectiveness of sotatercept in a cohort of 91 patients with PAH.
- ▪Results showed a mean improvement of 38 meters in the 6-minute walk test and a 56% decrease in NT-proBNP levels at 6 months.
- ▪Adverse events included gastrointestinal bleeding and telangiectasia, with some patients discontinuing treatment due to side effects.
Opening excerpt (first ~120 words) tap to expand
ORLANDO, Fla. — The activin signaling inhibitor sotatercept has been studied in multiple research trials, but little is known about safety and effectiveness in real-world patients with pulmonary arterial hypertension (PAH). That is, until now. Mayo Clinic researchers reported the first clinical setting outcomes among 91 patients receiving this first-in-class treatment.“We developed this registry to understand the real-world safety, efficacy, and tolerability of sotatercept in clinical practice. Overall, it was fairly safe, well tolerated, and effective, improving risk scores, 6-minute walk distance, and NT-proBNP [N-terminal pro-B-type natriuretic peptide],” said lead author Hilary M.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
